asymptomatic early-stage breast cancer. 10 In addition, monitoring of disease relapse with any tumor markers is not recommended. Use of MRI is optional and not universally recommended by experts in the field. Breast MRI advocates note its high sensitivity
Search Results
William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew Goetz, Lori J. Goldstein, Clifford A. Hudis, Steven J. Isakoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena Moran, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dorothy A. Shead, and Rashmi Kumar
David D. Buethe and Julio Pow-Sang
Reclassification Parameters Endorectal Multiparametric MRI Recently, a single-armed prospective trial 60 examined the efficacy of multiparametric T2-weighted endorectal MRI of the prostate with and without intravenous contrast. The accuracy of the
Parijatham S. Thomas
months. Screening with breast MRI was previously recommended for women with elevated risk for breast cancer predominately due to family history of breast cancer, but did not include those with history of AH or LCIS. 38 Due to insufficient evidence to
Andrea Cercek, Karyn A. Goodman, Carla Hajj, Emily Weisberger, Neil H. Segal, Diane L. Reidy-Lagunes, Zsofia K. Stadler, Abraham J. Wu, Martin R. Weiser, Philip B. Paty, Jose G. Guillem, Garrett M. Nash, Larissa K. Temple, Julio Garcia-Aguilar, and Leonard B. Saltz
clinical stage II/III rectal cancer (T3/4N1-2 based on endorectal ultrasound or MRI) who had been treated with initial chemotherapy followed by chemoradiation at MSKCC between 2007 and 2012. Patients were chosen based on the treating physician’s comfort
Louis Burt Nabors, Mario Ammirati, Philip J. Bierman, Henry Brem, Nicholas Butowski, Marc C. Chamberlain, Lisa M. DeAngelis, Robert A. Fenstermaker, Allan Friedman, Mark R. Gilbert, Deneen Hesser, Matthias Holdhoff, Larry Junck, Ronald Lawson, Jay S. Loeffler, Moshe H. Maor, Paul L. Moots, Tara Morrison, Maciej M. Mrugala, Herbert B. Newton, Jana Portnow, Jeffrey J. Raizer, Lawrence Recht, Dennis C. Shrieve, Allen K. Sills Jr, David Tran, Nam Tran, Frank D. Vrionis, Patrick Y. Wen, Nicole McMillian, and Maria Ho
difficult to determine accurately without sufficient tumor tissue. Review by an experienced neuropathologist is highly recommended. In addition, a postoperative MRI scan, with and without contrast, should be obtained 24 to 72 hours after surgery to document
Mary B. Daly, Robert Pilarski, Michael Berry, Saundra S. Buys, Meagan Farmer, Susan Friedman, Judy E. Garber, Noah D. Kauff, Seema Khan, Catherine Klein, Wendy Kohlmann, Allison Kurian, Jennifer K. Litton, Lisa Madlensky, Sofia D. Merajver, Kenneth Offit, Tuya Pal, Gwen Reiser, Kristen Mahoney Shannon, Elizabeth Swisher, Shaveta Vinayak, Nicoleta C. Voian, Jeffrey N. Weitzel, Myra J. Wick, Georgia L. Wiesner, Mary Dwyer, and Susan Darlow
the estimated 5-year risk of developing breast cancer exceeds 1%, consistent with recommendations for the average-risk population. Likewise, breast MRI screening in these carriers should begin when the estimated 5-year risk of developing breast cancer
Douglas B. Johnson and Jeffrey A. Sosman
melanoma; staging PET/CT scan and brain MRI showed no disseminated metastases. He was treated with high-dose interferon alpha for 1 year, through mid-2012. One month later, he noted supraclavicular fullness and monocular blurred vision. CT scans showed a
Emily Chan, Paul E. Wise, and A. Bapsi Chakravarthy
measured endoscopic distance given the variability in the use of distal landmarks to determine this measurement. Because endoscopic measurements of distance to the tumor can be misleading, pelvic imaging with CT, MRI, and endorectal ultrasound (EUS) can
Estanislao Arana, Francisco M. Kovacs, Ana Royuela, Beatriz Asenjo, Úrsula Pérez-Ramírez, Javier Zamora, and the Spanish Back Pain Research Network Task Force for the Improvement of Inter-Disciplinary Management of Spinal Metastasis
undergone an MRI in his department for spinal cord compression and whose ESCC scores had been rated by a tumor board. The tumor board comprised a medical oncologist, a radiation oncologist, a radiologist, a pathologist, an orthopedic surgeon, and a
Karisa C. Schreck, Andrew Guajardo, Doris D.M. Lin, Charles G. Eberhart, and Stuart A. Grossman
symptoms, with a maximum dosage of 4 mg/d, and were stopped 8 months after treatment initiation. His clinical condition and MRI scans steadily improved, and he became functionally independent. In February 2017, he presented to the hospital leaking
